AFT Pharmaceuticals Limited

NZSE:AFT Stock Report

Market Cap: NZ$319.8m

AFT Pharmaceuticals Valuation

Is AFT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AFT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AFT (NZ$3.05) is trading below our estimate of fair value (NZ$13.94)

Significantly Below Fair Value: AFT is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for AFT?

Other financial metrics that can be useful for relative valuation.

AFT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.7x
Enterprise Value/EBITDA13.8x
PEG Ratio1.1x

Price to Earnings Ratio vs Peers

How does AFT's PE Ratio compare to its peers?

The above table shows the PE ratio for AFT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average93.5x
BLT BLIS Technologies
33.7xn/aNZ$21.7m
002898 Sailong Pharmaceutical GroupLtd
189.9xn/aCN¥1.5b
1271 SunWay Biotech
134.7xn/aNT$5.9b
1734 Sinphar PharmaceuticalLtd
15.6xn/aNT$6.3b
AFT AFT Pharmaceuticals
20.5x18.1%NZ$319.8m

Price-To-Earnings vs Peers: AFT is good value based on its Price-To-Earnings Ratio (20.5x) compared to the peer average (93.5x).


Price to Earnings Ratio vs Industry

How does AFT's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a37.2%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a37.2%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: AFT is good value based on its Price-To-Earnings Ratio (20.5x) compared to the Global Pharmaceuticals industry average (23.9x).


Price to Earnings Ratio vs Fair Ratio

What is AFT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AFT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio20.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate AFT's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AFT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNZ$3.05
NZ$3.75
+23.0%
22.7%NZ$4.60NZ$2.90n/a2
Jul ’25NZ$3.00
NZ$3.75
+25.0%
22.7%NZ$4.60NZ$2.90n/a2
Jun ’25NZ$3.10
NZ$3.75
+21.0%
22.7%NZ$4.60NZ$2.90n/a2
May ’25NZ$3.02
NZ$3.70
+22.5%
24.3%NZ$4.60NZ$2.80n/a2
Apr ’25NZ$3.13
NZ$3.70
+18.2%
24.3%NZ$4.60NZ$2.80n/a2
Mar ’25NZ$3.24
NZ$4.51
+39.3%
30.2%NZ$6.14NZ$2.80n/a3
Feb ’25NZ$3.70
NZ$4.73
+27.8%
22.6%NZ$6.14NZ$3.55n/a3
Jan ’25NZ$3.50
NZ$4.73
+35.1%
22.6%NZ$6.14NZ$3.55n/a3
Dec ’24NZ$3.36
NZ$4.55
+35.3%
21.5%NZ$6.14NZ$3.55n/a4
Nov ’24NZ$3.40
NZ$4.61
+35.6%
19.9%NZ$6.14NZ$3.80n/a4
Oct ’24NZ$3.44
NZ$4.66
+35.5%
19.7%NZ$6.14NZ$3.80n/a4
Sep ’24NZ$3.50
NZ$4.66
+33.1%
19.7%NZ$6.14NZ$3.80n/a4
Aug ’24NZ$3.70
NZ$4.17
+12.6%
9.3%NZ$4.70NZ$3.80n/a3
Jul ’24NZ$3.60
NZ$4.17
+15.7%
9.3%NZ$4.70NZ$3.80NZ$3.003
Jun ’24NZ$3.75
NZ$4.17
+11.1%
9.3%NZ$4.70NZ$3.80NZ$3.103
May ’24NZ$3.36
NZ$3.89
+15.7%
16.3%NZ$4.70NZ$3.16NZ$3.023
Apr ’24NZ$3.46
NZ$3.89
+12.3%
16.3%NZ$4.70NZ$3.16NZ$3.133
Mar ’24NZ$3.36
NZ$3.89
+15.7%
16.3%NZ$4.70NZ$3.16NZ$3.243
Feb ’24NZ$3.78
NZ$3.89
+2.8%
16.3%NZ$4.70NZ$3.16NZ$3.703
Jan ’24NZ$3.65
NZ$5.23
+43.3%
35.7%NZ$8.26NZ$3.16NZ$3.504
Dec ’23NZ$3.77
NZ$5.23
+38.7%
35.7%NZ$8.26NZ$3.16NZ$3.364
Nov ’23NZ$3.72
NZ$5.51
+48.2%
29.5%NZ$8.26NZ$4.00NZ$3.404
Oct ’23NZ$3.30
NZ$5.69
+72.3%
32.5%NZ$8.26NZ$4.00NZ$3.443
Sep ’23NZ$3.45
NZ$5.69
+64.8%
32.5%NZ$8.26NZ$4.00NZ$3.503
Aug ’23NZ$3.62
NZ$5.69
+57.0%
32.5%NZ$8.26NZ$4.00NZ$3.703
Jul ’23NZ$3.61
NZ$5.69
+57.5%
32.5%NZ$8.26NZ$4.00NZ$3.603

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.